Equillium, Inc. Gains 52.78%

Equillium, Inc. (EQ:NASDAQ) rocketted at $1.23, a gain of 52.8%. On Tue, Feb 06, 2024, EQ:NASDAQ touched a New 2-Week High of $1.23. From Tue, Jan 23, 2024, the stock recorded 70.00% Up Days and 36.36% Green Days

About Equillium, Inc. (EQ:NASDAQ)

Equillium Inc is a biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is EQ001, which is a clinical stage first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. CD6 plays a central role in effector T cell activity, which drives a number of immuno-inflammatory diseases such as graft versus host disease, asthma, uveitis, colitis, lupus and multiple sclerosis.